Super-Enhancer Target Gene CBP/p300-Interacting Transactivator With Glu/Asp-Rich C-Terminal Domain, 2 Cooperates With Transcription Factor Forkhead Box J3 to Inhibit Pulmonary Vascular Remodeling

Abstract

The function of super-enhancers (SEs) in pulmonary hypertension (PH), especially in the proliferation of pulmonary artery smooth muscle cells (PASMCs), is currently unknown. We identified SEs-targeted genes in PASMCs with chromatin immunoprecipitation (ChIP)-sequence by H3K27ac antibody and proved that CBP/p300-interacting transactivator with Glu/Asp-rich C-terminal domain, 2 (CITED2) is an SEs-targeted gene through bioinformatics prediction, ChIP-PCR, dual-luciferase reporter gene assays and other experimental methods. We also found that the expression of CITED2 and the transcription factor Forkhead Box J3 (FOXJ3) was reduced in hypoxic mouse PASMCs. In addition, the expression of CITED2 and FOXJ3 also decreased in both the patients with idiopathic pulmonary arterial hypertension (iPAH) and the human PASMCs exposed to hypoxia. The decreased expression of CITED2 was reversed by co-transfection of FOXJ3 and SEs plasmids. Overexpressing of CITED2 attenuated the PASMCs proliferation induced by hypoxia. Lentiviral overexpression of CITED2 also reversed hypoxia-induced pulmonary hypertension mice model. Mechanically, the expression of CITED2 by affecting by FOXJ3, which binding with three SEs located in the about 2000 bp of TSS. In conclusion, we first identified that CITED2 is a kind of SEs-targeted gene, modulated by FOXJ3. The FOXJ3/SEs/CITED2 axis may become a new therapeutic target of PH.

Keywords

cell proliferation / pulmonary hypertension / super-enhancer

References

[1] M. Humbert, C. Guignabert, S. Bonnet, et al., “Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives,” European Respiratory Journal 53, no. 1 (2019): 1801887.

[2] Z. Luo, M. Tian, G. Yang, et al., “Hypoxia Signaling in Human Health and Diseases: Implications and Prospects for Therapeutics,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 218.

[3] J. Floyd, L. Wu, D. Hay Burgess, R. Izadnegahdar, D. Mukanga, and A. C. Ghani, “Evaluating the Impact of Pulse Oximetry on Childhood Pneumonia Mortality in Resource-Poor Settings,” Nature 528, no. 7580 (2015): S53–S59.

[4] T. H. G. Phan, P. Paliogiannis, G. K. Nasrallah, et al., “Emerging Cellular and Molecular Determinants of Idiopathic Pulmonary Fibrosis,” Cellular and Molecular Life Sciences 78, no. 5 (2021): 2031–2057.

[5] S. O. Simons, A. Elliott, M. Sastry, et al., “Chronic Obstructive Pulmonary Disease and Atrial Fibrillation: An Interdisciplinary Perspective,” European Heart Journal 42, no. 5 (2021): 532–540.

[6] S. V. Ochoa, L. Otero, A. F. Aristizabal-Pachon, F. Hinostroza, I. Carvacho, and Y. P. Torres, “Hypoxic Regulation of the Large-Conductance, Calcium and Voltage-Activated Potassium Channel, BK,” Frontiers in Physiology 12 (2021): 780206.

[7] X. Li, H. Cai, Y. Cai, Q. Zhang, Y. Ding, and Q. Zhuang, “Investigation of a Hypoxia-Immune-Related Microenvironment Gene Signature and Prediction Model for Idiopathic Pulmonary Fibrosis,” Frontiers in Immunology 12 (2021): 629854.

[8] P. Siques, E. Pena, J. Brito, and S. El Alam, “Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure,” Frontiers in Physiology 12 (2021): 690341.

[9] N. Sommer, H. A. Ghofrani, O. Pak, et al., “Current and Future Treatments of Pulmonary Arterial Hypertension,” British Journal of Pharmacology 178, no. 1 (2021): 6–30.

[10] J. Calder, A. Nagelberg, J. Luu, D. Lu, and W. W. Lockwood, “Resistance to BET Inhibitors in Lung Adenocarcinoma Is Mediated by Casein Kinase Phosphorylation of BRD4,” Oncogene 10, no. 3 (2021): 27.

[11] M. Zhong, R. Gao, R. Zhao, et al., “BET Bromodomain Inhibition Rescues PD-1-Mediated T-Cell Exhaustion in Acute Myeloid Leukemia,” Cell Death & Disease 13, no. 8 (2022): 671.

[12] L. Xiao, A. Parolia, Y. Qiao, et al., “Targeting SWI/SNF ATPases in Enhancer-Addicted Prostate Cancer,” Nature 601, no. 7893 (2022): 434–439.

[13] K. R. Kranc, H. Schepers, N. P. Rodrigues, et al., “Cited2 Is an Essential Regulator of Adult Hematopoietic Stem Cells,” Cell Stem Cell 5, no. 6 (2009): 659–665.

[14] H. Lawson, L. N. van de Lagemaat, M. Barile, et al., “CITED2 Coordinates Key Hematopoietic Regulatory Pathways to Maintain the HSC Pool in Both Steady-State Hematopoiesis and Transplantation,” Stem Cell Reports 16, no. 11 (2021): 2784–2797.

[15] Y. Jiang, J. Chen, C. Yue, et al., “The Role of miR-182-5p in Hepatocarcinogenesis of Trichloroethylene in Mice,” Toxicological Sciences 156, no. 1 (2017): 208–216.

[16] S. Jayaraman, M. Doucet, W. M. Lau, and S. L. Kominsky, “CITED2 Modulates Breast Cancer Metastatic Ability Through Effects on IKKalpha,” Molecular Cancer Research 14, no. 8 (2016): 730–739.

[17] R. B. Berlow, H. J. Dyson, and P. E. Wright, “Hypersensitive Termination of the Hypoxic Response by a Disordered Protein Switch,” Nature 543, no. 7645 (2017): 447–451.

[18] A. Usui-Ouchi, E. Aguilar, S. Murinello, et al., “An Allosteric Peptide Inhibitor of HIF-1alpha Regulates Hypoxia-Induced Retinal Neovascularization,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 45 (2020): 28297–28306.

[19] Y. Xing, X. Zheng, Y. Fu, et al., “Long Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension,” Molecular Therapy 27, no. 12 (2019): 2166–2181.

[20] Y. Fu, Y. Li, X. Wang, F. Li, and Y. Lu, “Overexpression of miR-425-5p Is Associated With Poor Prognosis and Tumor Progression in Non-Small Cell Lung Cancer,” Cancer Biomarkers 27, no. 2 (2020): 147–156.

[21] W. Yong, S. Deng, Y. Tan, and S. Li, “Circular RNA circSLC8A1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through Targeting the miR-106b-5p /FOXJ3 Axis,” Cell Cycle 20, no. 24 (2021): 2597–2606.

[22] C. Niu, S. Wang, J. Guo, et al., “BACH1 Recruits NANOG and Histone H3 Lysine 4 Methyltransferase MLL/SET1 Complexes to Regulate Enhancer-Promoter Activity and Maintains Pluripotency,” Nucleic Acids Research 49, no. 4 (2021): 1972–1986.

[23] S. Cui, Q. Wu, M. Liu, et al., “EphA2 Super-Enhancer Promotes Tumor Progression by Recruiting FOSL2 and TCF7L2 to Activate the Target Gene EphA2,” Cell Death & Disease 12, no. 3 (2021): 264.

[24] K. Miyagawa, M. Shi, P. I. Chen, et al., “Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes,” Circulation Research 124, no. 2 (2019): 211–224.

[25] H. Minemura, K. Takagi, A. Sato, et al., “CITED2 in Breast Carcinoma as a Potent Prognostic Predictor Associated With Proliferation, Migration and Chemoresistance,” Cancer Science 107, no. 12 (2016): 1898–1908.

[26] M. A. Rogers, V. Kalter, G. Marcias, M. Zapatka, S. Barbus, and P. Lichter, “CITED4 Gene Silencing in Colorectal Cancer Cells Modulates Adherens/Tight Junction Gene Expression and Reduces Cell Proliferation,” Journal of Cancer Research and Clinical Oncology 142, no. 1 (2015): 225–237.

[27] Z. Tang, G. He, J. Xu, and L. Zhongfu, “Knockdown of Cbp/P300-Interacting Transactivator With Glu/Asp-Rich Carboxy-Terminal Domain 2 Inhibits Cell Division and Increases Apoptosis in Gastric Cancer,” Journal of Surgical Research 211 (2017): 1–7.

[28] K. F. Cheung, J. Zhao, Y. Hao, et al., “CITED2 Is a Novel Direct Effector of Peroxisome Proliferator-Activated Receptor γ in Suppressing Hepatocellular Carcinoma Cell Growth,” Cancer 119, no. 6 (2012): 1217–1226.

[29] Y. T. Chou, C. H. Hsieh, S. H. Chiou, et al., “CITED2 Functions as a Molecular Switch of Cytokine-Induced Proliferation and Quiescence,” Cell Death and Differentiation 19, no. 12 (2012): 2015–2028.

[30] W. M. Lau, M. Doucet, D. Huang, K. L. Weber, and S. L. Kominsky, “CITED2 Modulates Estrogen Receptor Transcriptional Activity in Breast Cancer Cells,” Biochemical and Biophysical Research Communications 437, no. 2 (2013): 261–266.

[31] S. H. Shin, G. Y. Lee, M. Lee, et al., “Aberrant Expression of CITED2 Promotes Prostate Cancer Metastasis by Activating the Nucleolin-AKT Pathway,” Nature Communications 9, no. 1 (2018): 4113.

[32] M. Xu, X. Wu, Y. Li, et al., “CITED2 Mutation and Methylation in Children with Congenital Heart Disease,” Journal of Biomedical Science 21, no. 1 (2014): 7.

[33] I. Regel, L. Merkl, T. Friedrich, et al., “Pan-Histone Deacetylase Inhibitor Panobinostat Sensitizes Gastric Cancer Cells to Anthracyclines via Induction of CITED2,” Gastroenterology 143, no. 1 (2012): 99–109.e110.

[34] Y. Wang, H. Nie, X. He, et al., “The Emerging Role of Super Enhancer-Derived Noncoding RNAs in Human Cancer,” Theranostics 10, no. 24 (2020): 11049–11062.

[35] K. Yamagata, S. Nakayamada, and Y. Tanaka, “Critical Roles of Super-Enhancers in the Pathogenesis of Autoimmune Diseases,” Inflammation and Regeneration 40, no. 1 (2020): 517.

[36] W. Si, Z. Huang, X. Li, et al., “Super-Enhancer-Driven Sorting Nexin 5 Expression Promotes Dopaminergic Neuronal Ferroptosis in Parkinson's Disease Models,” Biochemical and Biophysical Research Communications 567 (2021): 35–41.

[37] C. Ma, X. Wang, L. Zhang, et al., “Super Enhancer-Associated Circular RNA-CircKrt4 Regulates Hypoxic Pulmonary Artery Endothelial Cell Dysfunction in Mice,” Arteriosclerosis, Thrombosis, and Vascular Biology 43, no. 7 (2023): 1179–1198.

[38] X. Chen, Z. Ji, A. Webber, and A. D. Sharrocks, “Genome-Wide Binding Studies Reveal DNA Binding Specificity Mechanisms and Functional Interplay Amongst Forkhead Transcription Factors,” Nucleic Acids Research 44, no. 4 (2016): 1566–1578.

[39] Y. Tang, W. Tian, S. Zheng, et al., “Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/Beta-Catenin Complex,” Research 6 (2023): 0289.

[40] M. S. Alexander, X. Shi, K. A. Voelker, et al., “Foxj3 Transcriptionally Activates Mef2c and Regulates Adult Skeletal Muscle Fiber Type Identity,” Developmental Biology 337, no. 2 (2010): 396–404.

[41] M. T. Fernandes, S. M. Calado, L. Mendes-Silva, and J. Bragança, “CITED2 and the Modulation of the Hypoxic Response in Cancer,” World Journal of Clinical Oncology 11, no. 5 (2020): 260–274.

[42] K. Sakaguchi, J. E. Herrera, S. Saito, et al., “DNA Damage Activates p53 Through a Phosphorylation-Acetylation Cascade,” Genes & Development 12, no. 18 (1998): 2831–2841.

[43] J. Du and Y. C. Yang, “Cited2 in Hematopoietic Stem Cell Function,” Current Opinion in Hematology 20, no. 4 (2013): 301–307.

[44] Z. Z. Wu, N. K. Sun, and C. C. Chao, “Knockdown of CITED2 Using Short-Hairpin RNA Sensitizes Cancer Cells to Cisplatin Through Stabilization of p53 and Enhancement of p53-Dependent Apoptosis,” Journal of Cellular Physiology 226, no. 9 (2011): 2415–2428.

[45] C. Zhang, S. Wang, X. Lu, et al., “POP1 Facilitates Proliferation in Triple-Negative Breast Cancer via m6A-Dependent Degradation of CDKN1A mRNA,” Research 7 (2024): 0472.

[46] K. Mattes, G. Berger, M. Geugien, E. Vellenga, and H. Schepers, “CITED2 Affects Leukemic Cell Survival by Interfering With p53 Activation,” Cell Death & Disease 8, no. 10 (2017): e3132.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.